Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen

Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen

Bacillus Calmette–Guérin (BCG) is the gold standard adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). However, given the current global shortage of BCG, new treatments are needed. We evaluated tumor microenvironment markers as potential BCG alternatives for NMIBC treatment. Programm...

Full description

Bibliographic Details
Main Authors: Han Kyu Chae, Wook Nam, Han Gwun Kim, Sharon Lim, Byeong-Joo Noh, So Won Kim, Gil Hyun Kang, Jong Yeon Park, Dae-Woon Eom, Sung Jin Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Subjects:
HER2 (human epidermal growth factor receptor-2)
PD-L1
PD1
CD8
ki67
ADC (antibody-drug conjugate)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.903297/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.903297/full

Similar Items